Simple blood test could spot hidden liver damage before It's too late

NCT ID NCT06366425

Ongoing Diagnosis Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score; if it's high, they are offered a FibroScan, a non-invasive scan that measures liver stiffness. The goal is to see how many people accept the screening and how often advanced fibrosis is found, which could lead to earlier treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this screening approach could help detect serious liver scarring earlier in people without known liver disease, allowing for timely care.
What could go wrong: This is an early-stage study with only 260 participants, so results may not apply to everyone. The screening might also miss some cases or cause unnecessary worry.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIBROSIS, LIVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease hepatocellular carcinoma metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIBROSIS, LIVER

Contacts and locations

Locations

CHU de Montpellier

Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.